# A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression

> **NCT00044681** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 258 (actual)

## Conditions studied

- Depressive Disorder
- Depressive Disorder, Major
- Depression

## Interventions

- **DRUG:** risperidone

## Key facts

- **NCT ID:** NCT00044681
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** —
- **Final completion:** 2004-03
- **Target enrollment:** 258 (ACTUAL)
- **Last updated:** 2011-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044681, "A Study of the Effectiveness and Safety of Risperidone to Augment SSRI Therapy in Patients With Treatment-resistant Depression". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00044681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*